DRRX Rasio cepet DURECT Corp

The price history of DURECT Corporation (DRRX) demonstrates the current indicator 0.98. DURECT Corporation develops liver therapies, focusing on the treatment of alcoholic hepatitis and the advancement of the drug Larsucosterol. Patent protections for molecules and strict regulatory requirements create barriers for competitors. However, the lack of a broad portfolio of finished products and the reliance on a single platform increase investment risks.

Developing liver drugs requires colossal expenditures, making the ability of DURECT Corporation (DRRX) to fund research without selling off assets critical for survival. This metric aggregates cash and accounts receivable while excluding illiquid inventories, allowing the market to assess the risk of a liquidity gap and the business's resilience to clinical trial failures via the hard liability coverage ratio.